biostudies-literatureEscamilla-Rivera VNCATS NIH HHSNHLBI NIH HHS1983-1993https://www.ebi.ac.uk/biostudies/studies/S-EPMC7256361biostudies-literatureUnknown135(22)Polyclonal anti-D (Rh immune globulin [RhIg]) therapy has mitigated hemolytic disease of the newborn over the past half century, although breakthrough anti-D alloimmunization still occurs in some treated females. We hypothesized that antiviral responses may impact the efficacy of immunoprophylaxis therapy in a type 1 interferon (IFN)-dependent manner and tested this hypothesis in a murine model of KEL alloimmunization. Polyclonal anti-KEL immunoprophylaxis (KELIg) was administered to wild-type or knockout mice in the presence or absence of polyinosinic-polycytidilic acid (poly[I:C]), followed by the transfusion of murine red blood cells (RBCs) expressing the human KEL glycoprotein. Anti-KEL alloimmunization, serum cytokines, and consumption of the transfused RBCs were evaluated longitudinaBloodPoly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice.PMC7256361P01 HL132819R01 HL126076K08 HL141446T32 HL007974UL1 TR001863Forsmo JELiu JLuckey CJHendrickson JEEscamilla-Rivera VEisenbarth SCGibb DRStowell SRSanthanakrishnan MFoxman EFLiu DHudson KEZimring JCfalsePoly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice.Polyclonal anti-D (Rh immune globulin [RhIg]) therapy has mitigated hemolytic disease of the newborn over the past half century, although breakthrough anti-D alloimmunization still occurs in some treated females. We hypothesized that antiviral responses may impact the efficacy of immunoprophylaxis therapy in a type 1 interferon (IFN)-dependent manner and tested this hypothesis in a murine model of KEL alloimmunization. Polyclonal anti-KEL immunoprophylaxis (KELIg) was administered to wild-type or knockout mice in the presence or absence of polyinosinic-polycytidilic acid (poly[I:C]), followed by the transfusion of murine red blood cells (RBCs) expressing the human KEL glycoprotein. Anti-KEL alloimmunization, serum cytokines, and consumption of the transfused RBCs were evaluated longitudina2020-01-01T00:00:00Z2020 May2025-04-19T18:07:02.803Z2022-02-10T11:57:28.686ZS-EPMC72563613226637810.1182/blood.2020005018